We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585192

CAS#: 4388-82-3

Description: Barbexaclone is a salt compound of phenobarbital and levopropylhexedrine.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-26. Prices are subject to change without notice.

Barbexaclone is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 585192
Name: Barbexaclone
CAS#: 4388-82-3
Chemical Formula: C22H33N3O3
Exact Mass: 387.2522
Molecular Weight: 387.524
Elemental Analysis: C, 68.19; H, 8.58; N, 10.84; O, 12.39

Synonym: Barbexaclone; Maliasin; Su 42; Su42; Su42

IUPAC/Chemical Name: 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione compound with (S)-1-cyclohexyl-N-methylpropan-2-amine (1:1)


InChi Code: InChI=1S/C12H12N2O3.C10H21N/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;1-9(11-2)8-10-6-4-3-5-7-10/h3-7H,2H2,1H3,(H2,13,14,15,16,17);9-11H,3-8H2,1-2H3/t;9-/m.0/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Bolukbasi F, Delil S, Bulus E, Senturk A, Yeni N, Karaagac N. End of the barbexaclone era: an experience of treatment withdrawal. Epileptic Disord. 2013 Sep;15(3):311-3. doi: 10.1684/epd.2013.0605. PubMed PMID: 23981808.

2: Iven H, Feldbusch E. Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. Naunyn Schmiedebergs Arch Pharmacol. 1983 Sep;324(2):153-9. PubMed PMID: 6139756.

3: Borromei A, Caramelli R, Cipriani G, Giancola LC, Guerra L, Lozito A. [Neurotraumatology and post-traumatic epilepsy. Prevention, treatment and long-term follow-up. Barbexaclone + phenobarbital (maliasin) versus diphenylhydantoin, phenobarbital, primidone, carbamazepine]. Minerva Med. 1987 Nov 30;78(22):1687-705. Review. Italian. PubMed PMID: 3320814.

4: Darcın AE, Dilbaz N, Okay IT. Barbexaclone abuse in a cannabis ex-user. Subst Abus. 2010 Oct;31(4):270-2. doi: 10.1080/08897077.2010.514246. PubMed PMID: 21038181.

5: Perucca E, Grimaldi R, Ruberto G, Gelmi C, Trimarchi F, Crema A. Comparative kinetics of phenobarbital after administration of the acid and the propylhexedrine salt (barbexaclone). Eur J Clin Pharmacol. 1986;29(6):729-30. PubMed PMID: 3709618.

6: Bretas AD, de Lemos Neto M. [Effects of barbexaclone on the electroencephalogram, motor activity and experimental convulsions]. Arq Neuropsiquiatr. 1983 Dec;41(4):356-66. Spanish. PubMed PMID: 6661099.

7: Reis TT, Maia Filho PC, Cechini PC. [Clinical evaluation of the therapeutic value of barbexaclone including determination of plasma levels of the barbiturate]. Arq Neuropsiquiatr. 1980 Mar;38(1):93-8. Portuguese. PubMed PMID: 6105861.

8: Salles Barbosa MF. [Barbexaclone in the treatment of cerebral dysrhythmia]. Arq Neuropsiquiatr. 1978 Sep;36(3):245-9. Portuguese. PubMed PMID: 28716.

9: Canger R, Wahl L. [On the treatment of epilepsy with Maliasin]. Nervenarzt. 1968 Oct;39(10):476-8. German. PubMed PMID: 4972878.

10: Cabral Filho G, Mariani MD, Fonseca LF, Soares Neto V, Bolina ND. [Clinical and laboratory experience in the treatment of epilepsy with barbexaclone. Considerations on 29 cases]. Arq Neuropsiquiatr. 1980 Sep;38(3):269-77. Portuguese. PubMed PMID: 6110418.

11: Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI. Barbexaclone use in pregnancy. Saudi Med J. 2004 Feb;25(2):245-6. PubMed PMID: 14968233.

12: Visintini D, Calzetti S, Mancia D. [Barbexaclone in the treatment of the epilepsies (author's transl)]. Riv Patol Nerv Ment. 1981 Jan-Feb;102(1):29-37. Italian. PubMed PMID: 7345550.


14: de Lima JM, Oliveira C, Duro LA, Poiares Nde M. [Effect of barbexaclone in convulsive crisis difficult to control]. Arq Neuropsiquiatr. 1980 Mar;38(1):89-92. Portuguese. PubMed PMID: 6105860.

15: Oliveira C, Fernandes I, De Lima JM, Musse R. [Clinical trial with barbexaclone in epilepsies]. Arq Neuropsiquiatr. 1977 Mar;35(1):68-72. Portuguese. PubMed PMID: 14606.

16: Oliveira C, Fernandes I, de Lima JM, Duro LA, da Silva CV. [Effects of barbexaclone in Lennox-Gastaut syndrome]. Arq Neuropsiquiatr. 1978 Dec;36(4):340-9. Portuguese. PubMed PMID: 36058.

17: Bragatti JH, Caleffi GH, Prenna FJ. [Clinical trial with a new anti-epileptic: barbexaclone]. Arq Neuropsiquiatr. 1977 Sep;35(3):277-81. Portuguese. PubMed PMID: 20070.

18: Becker B. [Experience with the antiepileptic maliasin]. Med Welt. 1968 Mar 2;9:577-80. German. PubMed PMID: 5719393.

19: Oliveira C, Fernandes I, de Lima JM. [Re-evaluation of barbexaclone in 20 epileptic patients]. Arq Neuropsiquiatr. 1978 Jun;36(2):135-8. Portuguese. PubMed PMID: 26322.

20: Steinhoff BJ, Stodieck SR. Temporary abolition of seizure activity by flumazenil in a case of valproate-induced non-convulsive status epilepticus. Seizure. 1993 Sep;2(3):261-5. PubMed PMID: 8162392.